首页> 美国卫生研究院文献>Clinical Kidney Journal >Therapeutic drug monitoring of enteric-coated mycophenolate sodium by limited sampling strategies is associated with a high rate of failure
【2h】

Therapeutic drug monitoring of enteric-coated mycophenolate sodium by limited sampling strategies is associated with a high rate of failure

机译:通过有限的采样策略监测肠溶性麦考酚酸钠的治疗药物与高失败率相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTherapeutic drug monitoring of mycophenolic acid (MPA) is usually performed with a limited sampling strategy (LSS), which relies on a limited number of blood samples and subsequent extrapolation of the global exposure to MPA. LSS is usually performed successfully with mycophenolate mofetil (MMF), but data on enteric-coated mycophenolate sodium (EC-MPS) are scarce. Here, we evaluated the feasibility of 6-h LSS therapeutic drug monitoring with EC-MPS compared with MMF monitoring among kidney transplant recipients.
机译:背景技术对霉酚酸(MPA)的治疗药物监测通常采用有限采样策略(LSS)进行,该策略依赖于有限数量的血液样本以及随后对MPA总体暴露量的推断。 LSS通常可通过霉酚酸酯(MMF)成功进行,但有关肠溶霉酚酸钠(EC-MPS)的数据很少。在这里,我们评估了在肾脏移植接受者中,使用EC-MPS进行6小时LSS治疗药物监测与进行MMF监测相比的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号